Rubius Therapeutics, Inc. (RUBY) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 15.8M |
| Enterprise Value | 2.04M |
| P/E Ratio | -0.02 |
| PEG Ratio | 0 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | 0.34 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | 0.08 |
| Fiscal Year | December 31, 2022 |
| Most Recent Quarter | December 31, 2022 |
| Profit Margin | 0 |
| Operating Margin | 0 |
| Return On Assets | -10.01 |
| Return On Equity | -2.38 |
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | 0 |
| EBITDA | -169.55M |
| Net Income | -230.86M |
| Diluted EPS | -2.56 |
| Total Cash | 18.93M |
| Total Cash/Share | 0.21 |
| Total Debt | 1.1M |
| Total Debt/Equity | 0.07 |
| Current Ratio | 2.54 |
| Book Value Per Share | 0.17 |
| 52-Week Change | -77.56 |
| 52-Week High | 0.38 |
| 52-Week Low | 0 |
| Moving Average 50 Days | 0.02 |
| Moving Average 200 Days | 0.02 |
| Average Volume | 99,535 |
| Shares Outstanding | 0 |
| % Held by Institutions | 3.27 |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |